TH9507 Extension Study in Patients With HIV- Associated Lipodystrophy
Completed
Theratechnologies
Phase 3
2007-08-01
HIV lipodystrophy affects a significant proportion of patients treated with combination
antiretroviral therapy (ART) and is characterized by excess visceral fat accumulation, loss
of extremity and subcutaneous fat, in association with dyslipidemia and insulin resistance.
Data from the first Phase 3 multicenter, randomized, placebo-controlled trial demonstrated
that daily administration of 2mg TH9507, a growth hormone releasing factor (GRF), to HIV-
infected patients with excess of abdominal fat accumulation for 26 weeks resulted in
decreases in visceral adipose tissue (VAT) and trunk fat, with lesser changes in limb fat and
subcutaneous adipose tissue (SAT). The present study is aimed at confirming the observations
made during the first Phase 3 study.
Long-term Observational Study in HIV Subjects Exposed to EGRIFTA®
Terminated
Theratechnologies
2013-02-01
The purpose of this observational, 10-year, prospective cohort study is to assess the
potential safety concerns of long-term exposure to EGRIFTA® in HIV-infected subjects with
abdominal lipohypertrophy compared with a similar group of subjects not exposed to EGRIFTA®.
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
Terminated
Theratechnologies
Phase 4
2012-06-01
To show the non-inferiority of EGRIFTA® vs. placebo in the development or progression of
Diabetic Retinopathy in HIV-infected subjects with concomitant abdominal lipohypertrophy and
Type 2 diabetes mellitus (T2DM).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
